RecruitingPhase 3NCT07724132

An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

Alzheimer's Disease- Systematic Multi-Arm Adaptive Randomised Trial

Sponsor

University College, London

Enrollment

1,200 participants

Start Date

Jul 24, 2026

Study Type

INTERVENTIONAL

Conditions

Alzheimer's Disease (AD)Mild Cognitive Impairment Due to Alzheimer's Disease Alzheimer Disease Dementia

Summary

A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzheimer's disease in the UK.

Eligibility

Min Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Atomoxetine, a drug called Metformin 1000 mg Oral Tablet, and others for people with alzheimer disease dementia, alzheimer's disease (ad), and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 55 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.